argenx SE (FRA:1AE) Other Long-Term Liabilities: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1AE argenx SE FRA:1AE
80 GF Score
Price €851.20
GF Value €1,291.01
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is argenx SE Other Long-Term Liabilities?

argenx SE FRA:1AE -1.18% 80 Other Long-Term Liabilities is €0 Mil as of Jun. 2026. GuruFocus rates FRA:1AE with a GF Score™ of 80/100 and a GF Value™ of €1,291.01 (Significantly Undervalued). The stock has 4 warning signs investors should review.

argenx SE's other long-term liabilities for the quarter that ended in Jun. 2026 was €0 Mil.

argenx SE's quarterly other long-term liabilities increased from Jun. 2025 (€-0 Mil) to Dec. 2025 (€0 Mil) but then declined from Dec. 2025 (€0 Mil) to Jun. 2026 (€0 Mil).

argenx SE's annual other long-term liabilities increased from Dec. 2023 (€-0 Mil) to Dec. 2024 (€-0 Mil) and increased from Dec. 2024 (€-0 Mil) to Dec. 2025 (€0 Mil).

argenx SE Other Long-Term Liabilities Related Terms

argenx SE Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for argenx SE's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Other Long-Term Liabilities Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 -0.00 -0.00 0.00

argenx SE Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 0.00
FRA:1AE
80GF Score
argenx SE FRA:1AE
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0 Mil mean?
argenx SE (FRA:1AE) has a Other Long-Term Liabilities of €0 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on argenx SE and its competitors.
Is argenx SE's Other Long-Term Liabilities too high?
argenx SE's current Other Long-Term Liabilities is €0 Mil. Overall, argenx SE has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Other Long-Term Liabilities compare to VRTX and REGN?
argenx SE's Other Long-Term Liabilities of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on argenx SE and its competitors. argenx SE's current Other Long-Term Liabilities is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,291.01, compared to a current price of €851.20 — trading 34.1% below its estimated fair value. The current Other Long-Term Liabilities is €0 Mil. argenx SE's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Other Long-Term Liabilities is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (FRA:1AE) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of €851.20 is trading 34.1% below its estimated GF Value™ of €1,291.01. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for FRA:1AE:

  • Other Long-Term Liabilities: €0 Mil
  • GF Value™: €1,291.01 vs. price of €851.20 (34.1% below fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
80GF Score

Get the complete analysis for FRA:1AE

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€851.20
Price
€1,291.01
GF Value